WallStreetZenWallStreetZen

NYSEMKT: NNVC
Nanoviricides Inc Stock Forecast, Predictions & Price Target

OverviewForecast
EarningsRevenueDividendOwnership

Analyst price target for NNVC

Based on 1 analyst offering 12 month price targets for Nanoviricides Inc

Min Forecast
$6.00+328.57%
Avg Forecast
$6.00+328.57%
Max Forecast
$6.00+328.57%

Should I buy or sell NNVC stock?

Based on 1 analyst offering ratings for Nanoviricides Inc.

Buy
Strong Buy
0 analysts 0%
Buy
1 analysts 100%
Hold
0 analysts 0%
Sell
0 analysts 0%
Strong Sell
0 analysts 0%
Although NNVC's forecast from analysts indicates a "Buy", our proven Zen Rating quant model rates NNVC as a "Sell". Stocks with a Zen Rating of Sell have had an average return of -6.47% per year. Learn More

Be the first to know when Wall Street analysts revise their NNVC stock forecasts and price targets.

NNVC stock forecasts by analyst

Analyst / FirmRatingActionPrice TargetUpside/DownsideDateAnalyst Color
lockedlocked$00.00+00.00%2026-07-06

1 of 1

Forecast return on equity

Is NNVC forecast to generate an efficient return?

Company
N/A
Industry
21.15%
Market
167.34%

Forecast return on assets

Is NNVC forecast to generate an efficient return on assets?

Company
N/A
Industry
23.84%

NNVC earnings per share forecast

What is NNVC's earnings per share in the next 3 years based on estimates from 4 analysts?

Avg 1 year Forecast
-$0.47
Avg 2 year Forecast
-$0.41
Avg 3 year Forecast
$0.51

NNVC revenue forecast

What is NNVC's revenue in the next 3 years based on estimates from 3 analysts?

Avg 1 year Forecast
$0.0
Avg 2 year Forecast
$0.0
Avg 3 year Forecast
$78.0M

NNVC vs Biotech Stocks

TickerPricePrice TargetUp/downsideConsensus
NNVC$1.40$6.00+328.57%Buy
EDSA$3.72N/AN/A
BCTX$4.02N/AN/A
ATNM$1.11N/AN/A
MGX$1.03$6.00+482.52%Strong Buy
View Top Biotech Stocks

Nanoviricides Stock Forecast FAQ

Is Nanoviricides Stock a good buy in 2026, according to Wall Street analysts?

The consensus among 1 Wall Street analyst covering (NYSEMKT: NNVC) stock is to Buy NNVC stock.

Out of 1 analyst, 0 (0%) are recommending NNVC as a Strong Buy, 1 (100%) are recommending NNVC as a Buy, 0 (0%) are recommending NNVC as a Hold, 0 (0%) are recommending NNVC as a Sell, and 0 (0%) are recommending NNVC as a Strong Sell.

If you're new to stock investing, here's how to buy Nanoviricides stock.

What is NNVC's earnings growth forecast for 2027-2028?

(NYSEMKT: NNVC) Nanoviricides's forecast annual earnings growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast earnings growth rate of 11.3%, and while it is not forecast to beat the US market's average forecast earnings growth rate of 32.52%.

Nanoviricides's earnings in 2026 is -$8,218,509.On average, 4 Wall Street analysts forecast NNVC's earnings for 2027 to be -$11,976,330, with the lowest NNVC earnings forecast at -$11,506,670, and the highest NNVC earnings forecast at -$12,328,575. On average, 4 Wall Street analysts forecast NNVC's earnings for 2027 to be -$10,544,378, with the lowest NNVC earnings forecast at -$11,506,670, and the highest NNVC earnings forecast at -$9,380,438.

In 2028, NNVC is forecast to generate $13,017,750 in earnings, with the lowest earnings forecast at $12,507,250 and the highest earnings forecast at $13,400,625.

What is NNVC's revenue growth forecast for 2027-2028?

(NYSEMKT: NNVC) Nanoviricides's forecast annual revenue growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 31.23%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 14.52%.

Nanoviricides's revenue in 2026 is $0.On average, 3 Wall Street analysts forecast NNVC's revenue for 2027 to be $0, with the lowest NNVC revenue forecast at $0, and the highest NNVC revenue forecast at $0. On average, 3 Wall Street analysts forecast NNVC's revenue for 2027 to be $0, with the lowest NNVC revenue forecast at $0, and the highest NNVC revenue forecast at $0.

In 2028, NNVC is forecast to generate $1,991,715,750 in revenue, with the lowest revenue forecast at $1,913,609,250 and the highest revenue forecast at $2,050,295,625.

What is NNVC's forecast return on assets (ROA) for 2027-2029?

(NYSEMKT: NNVC) forecast ROA is N/A, which is lower than the forecast US Biotechnology industry average of 23.84%.

What is NNVC's Price Target?

According to 1 Wall Street analyst that have issued a 1 year NNVC price target, the average NNVC price target is $6.00, with the highest NNVC stock price forecast at $6.00 and the lowest NNVC stock price forecast at $6.00.

The Wall Street analyst predicted that Nanoviricides's share price could reach $6.00 by Jul 6, 2027. The average Nanoviricides stock price prediction forecasts a potential upside of 328.57% from the current NNVC share price of $1.40.

What is NNVC's Earnings Per Share (EPS) forecast for 2027-2028?

(NYSEMKT: NNVC) Nanoviricides's current Earnings Per Share (EPS) is -$0.41. On average, analysts forecast that NNVC's EPS will be -$0.47 for 2027, with the lowest EPS forecast at -$0.45, and the highest EPS forecast at -$0.48. On average, analysts forecast that NNVC's EPS will be -$0.41 for 2027, with the lowest EPS forecast at -$0.45, and the highest EPS forecast at -$0.37. In 2028, NNVC's EPS is forecast to hit $0.51 (min: $0.49, max: $0.53).

What is NNVC's forecast return on equity (ROE) for 2027-2029?

(NYSEMKT: NNVC) forecast ROE is N/A, which is considered weak.
©2026 WallStreetZen
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletter
Stock Tools
Top Performing AnalystsStock ScreenerStock ForecastTrending StocksStrong Buy StocksHighest Earnings StocksBest Dividend Paying StocksStatisticsStock Market SectorsStock Market IndustriesHow to Buy Stocks Online
Stock Ideas
Buy The DipBiggest Stock Gainers TodayBiggest Stock Losers Today52 Week High Stocks52 Week Low StocksMost Active Stocks TodayMost Undervalued StocksBest Penny Stocks to Buy NowBest Stocks Under $5Best Stocks Under $10
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.